Publicaciones en colaboración con investigadores/as de Charité (84)

2024

  1. Covering Hierarchical Dirichlet Mixture Models on binary data to enhance genomic stratifications in onco-hematology

    PLoS Computational Biology, Vol. 20, Núm. 2

  2. Embolization of percutaneous left atrial appendage closure devices: timing, management and clinical outcomes

    Cardiovascular Revascularization Medicine

  3. Endothelial Activation and Stress Index (EASIX) to predict mortality after allogeneic stem cell transplantation: A prospective study

    Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 1

  4. Graft-versus-Host Disease Prophylaxis with Post- Transplantation Cyclophosphamide in Chronic Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation from an Unrelated or Mismatched Related Donor: A Comparative Study from the Chronic Malignancies Working Party of the EBMT (CMWP-EBMT)

    Transplantation and Cellular Therapy, Vol. 30, Núm. 1, pp. 93.e1-93.e12

  5. Outcomes after surgical revascularization in diabetic patients

    Interdisciplinary cardiovascular and thoracic surgery, Vol. 38, Núm. 2

  6. Profiling the dysregulated immune response in sepsis: overcoming challenges to achieve the goal of precision medicine

    The Lancet Respiratory Medicine, Vol. 12, Núm. 4, pp. 305-322

  7. Regional, sex, and age inequities in asthma hospital admissions in Spain and Portugal

    Clinical and Translational Allergy

  8. Sensory Schwann cells set perceptual thresholds for touch and selectively regulate mechanical nociception

    Nature Communications, Vol. 15, Núm. 1

  9. Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia

    American Journal of Hematology, Vol. 99, Núm. 4, pp. 586-595

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Clinical outcomes and quality of life after contemporary isolated coronary bypass grafting: a prospective cohort study

    International journal of surgery (London, England), Vol. 109, Núm. 4, pp. 707-715

  3. Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY (Leukemia, (2023), 37, 2, (339-347), 10.1038/s41375-022-01802-y)

    Leukemia

  4. Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY

    Leukemia, Vol. 37, Núm. 2, pp. 339-347

  5. Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation

    Leukemia, Vol. 37, Núm. 7, pp. 1521-1529

  6. In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities

    Blood cancer discovery, Vol. 4, Núm. 2, pp. 150-169

  7. One treatment with onabotulinumtoxinA relieves symptoms of overactive bladder in patients refractory to one or more oral medications

    Neurourology and Urodynamics, Vol. 42, Núm. 6, pp. 1203-1213

  8. Severe cytopenia after CD19 CAR T-cell therapy: A retrospective study from the EBMT Transplant Complications Working Party

    Journal for ImmunoTherapy of Cancer, Vol. 11, Núm. 4

2022

  1. Building a Healthcare Alliance for Resourceful Medicine Offensive Against Neoplasms in Hematology Added Value Framework for Hematologic Malignancies: A Comparative Analysis of Existing Tools

    Value in Health, Vol. 25, Núm. 10, pp. 1760-1767

  2. Clinical event rate in patients with and without left main disease undergoing isolated coronary artery bypass grafting: results from the European DuraGraft Registry

    European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, Vol. 62, Núm. 4

  3. Corrigendum to “OAB-005: Update of safety and efficacy of Isatuximab short-duration fixed-volume infusion plus Bortezomib, Lenalidomide, and Dexamethasone combined therapy for NDMM ineligible/with no immediate intent for ASCT” [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) S3-S4](S2152265021X00122)

    Clinical Lymphoma, Myeloma and Leukemia